Adaptimmune Therapeutics PLC (NASDAQ:ADAP) Given Average Rating of “Reduce” by Analysts

Shares of Adaptimmune Therapeutics PLC (NASDAQ:ADAP) have earned a consensus recommendation of “Reduce” from the eight research firms that are covering the company, Marketbeat Ratings reports. Two analysts have rated the stock with a sell rating, five have assigned a hold rating and one has issued a buy rating on the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $1.3517.

A number of research firms recently commented on ADAP. Guggenheim cut shares of Adaptimmune Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 29th. HC Wainwright restated a “neutral” rating on shares of Adaptimmune Therapeutics in a research note on Tuesday, July 29th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Adaptimmune Therapeutics in a research report on Wednesday, October 8th.

Insider Buying and Selling

In other Adaptimmune Therapeutics news, Director Ali Behbahani sold 14,671,794 shares of the stock in a transaction dated Monday, August 18th. The shares were sold at an average price of $0.01, for a total transaction of $146,717.94. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders have sold 19,803,000 shares of company stock worth $198,030 over the last quarter. 12.44% of the stock is owned by corporate insiders.

Institutional Trading of Adaptimmune Therapeutics

A number of institutional investors have recently modified their holdings of ADAP. Long Focus Capital Management LLC boosted its holdings in Adaptimmune Therapeutics by 15.9% in the 1st quarter. Long Focus Capital Management LLC now owns 23,756,687 shares of the biotechnology company’s stock worth $4,680,000 after buying an additional 3,262,294 shares during the period. Two Seas Capital LP lifted its position in shares of Adaptimmune Therapeutics by 10.0% during the second quarter. Two Seas Capital LP now owns 22,580,701 shares of the biotechnology company’s stock worth $5,413,000 after acquiring an additional 2,051,016 shares in the last quarter. Acadian Asset Management LLC boosted its holdings in shares of Adaptimmune Therapeutics by 334.8% in the first quarter. Acadian Asset Management LLC now owns 2,218,215 shares of the biotechnology company’s stock worth $424,000 after acquiring an additional 1,707,999 shares during the period. Empirical Finance LLC bought a new position in shares of Adaptimmune Therapeutics in the second quarter worth $192,000. Finally, B. Riley Wealth Advisors Inc. purchased a new position in shares of Adaptimmune Therapeutics in the third quarter valued at $65,000. 31.37% of the stock is currently owned by hedge funds and other institutional investors.

Adaptimmune Therapeutics Price Performance

ADAP opened at $0.06 on Friday. Adaptimmune Therapeutics has a fifty-two week low of $0.04 and a fifty-two week high of $0.86. The firm has a market capitalization of $15.35 million, a PE ratio of -0.09 and a beta of 2.49. The company’s 50-day moving average is $0.10 and its 200 day moving average is $0.18.

Adaptimmune Therapeutics (NASDAQ:ADAP) last issued its quarterly earnings data on Wednesday, August 13th. The biotechnology company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.15) by $0.04. Adaptimmune Therapeutics had a negative return on equity of 163.73% and a negative net margin of 260.82%.The business had revenue of $13.68 million for the quarter, compared to analysts’ expectations of $11.04 million. As a group, analysts expect that Adaptimmune Therapeutics will post -0.14 EPS for the current year.

About Adaptimmune Therapeutics

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.